申请人:Andrews Mark
公开号:US20100113422A1
公开(公告)日:2010-05-06
The present invention provides a compound of formula (I):
or a pharmaceutically acceptable salt thereof wherein the variables R
1
, R
2
, R
3a
, R
3b
, R
3b
, R
3d
, and R
100
are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a 5-HT
2c
receptor-mediated disorders with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I).
本发明提供了式(I)的化合物:或其药学上可接受的盐,其中变量R1、R2、R3a、R3b、R3b、R3d和R100如本文所定义。本发明还涉及包括式(I)化合物的制药组合物,以及使用式(I)的化合物或包括式(I)的制药组合物治疗5-HT2c受体介导的疾病的方法。